Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21322986rdf:typepubmed:Citationlld:pubmed
pubmed-article:21322986lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:21322986lifeskim:mentionsumls-concept:C0007097lld:lifeskim
pubmed-article:21322986lifeskim:mentionsumls-concept:C1517004lld:lifeskim
pubmed-article:21322986pubmed:issue1lld:pubmed
pubmed-article:21322986pubmed:dateCreated2011-2-17lld:pubmed
pubmed-article:21322986pubmed:abstractTextTransitional-cell carcinoma of the bladder has been induced by chronic oral administration of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) in C3H/He mice, and successfully transplanted in syngeneic animals. Evaluation of the effectiveness of several chemotherapeutic agents on this tumor indicated that cyclophosphamide and cis-diammine dichloroplatinum (CACP) significantly inhibited tumor growth and prolonged the median survival time of tumor-bearing animals. When administered before formation of palpable tumors, cyclophosphamide completely prevented growth of the implants in 100 per cent of animals; when administered after the growth of larger, palpable tumors, cyclophosphamide inhibited tumor growth in all animals and produced a "cure" in 45 per cent. Combination chemotherapy with cyclophosphamide and CACP was more effective than either drug used as a single agent. Adriamycin, dactinomycin, and mitomycin C administered individually exhibited limited activity while 5-fluorouracil, CCNU (1-2 choloroethyl-3-cyclohexyl-1-nitrosourea), BCNU (1,3-bis [2-chloroethyl]-1-nitrosourea), methrotrexate, and hydroxyurea were ineffective against this tumor. The consistent growth pattern, the histologic similarity to bladder cancer in human beings, and the successful propagation in syngeneic animals, make the FANFT-induced tumor a suitable model for chemotherapy of bladder carcinoma in human beings.lld:pubmed
pubmed-article:21322986pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21322986pubmed:languageenglld:pubmed
pubmed-article:21322986pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21322986pubmed:citationSubsetIMlld:pubmed
pubmed-article:21322986pubmed:statusMEDLINElld:pubmed
pubmed-article:21322986pubmed:monthJullld:pubmed
pubmed-article:21322986pubmed:issn0090-4295lld:pubmed
pubmed-article:21322986pubmed:authorpubmed-author:PerskyLLlld:pubmed
pubmed-article:21322986pubmed:authorpubmed-author:SolowayM SMSlld:pubmed
pubmed-article:21322986pubmed:authorpubmed-author:DeKernionJ...lld:pubmed
pubmed-article:21322986pubmed:issnTypePrintlld:pubmed
pubmed-article:21322986pubmed:volume4lld:pubmed
pubmed-article:21322986pubmed:ownerNLMlld:pubmed
pubmed-article:21322986pubmed:authorsCompleteYlld:pubmed
pubmed-article:21322986pubmed:pagination63-8lld:pubmed
pubmed-article:21322986pubmed:meshHeadingpubmed-meshheading:21322986...lld:pubmed
pubmed-article:21322986pubmed:meshHeadingpubmed-meshheading:21322986...lld:pubmed
pubmed-article:21322986pubmed:meshHeadingpubmed-meshheading:21322986...lld:pubmed
pubmed-article:21322986pubmed:meshHeadingpubmed-meshheading:21322986...lld:pubmed
pubmed-article:21322986pubmed:meshHeadingpubmed-meshheading:21322986...lld:pubmed
pubmed-article:21322986pubmed:meshHeadingpubmed-meshheading:21322986...lld:pubmed
pubmed-article:21322986pubmed:year1974lld:pubmed
pubmed-article:21322986pubmed:articleTitleChemotherapy of experimental transitional-cell carcinoma.lld:pubmed
pubmed-article:21322986pubmed:affiliationDepartment of Surgery, Division of Urology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.lld:pubmed
pubmed-article:21322986pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21322986pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed